Phenytoin for neuropathic pain and fibromyalgia in adults

Birse, Fraser; Derry, Sheena; Moore, Richard A.

doi:10.1002/14651858.cd009485

Cited by 4 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rather than analyzing the quality of evidence of clinical trials using these substances, we were interested in assigning the active principle and IUPAC names to the reported compounds, to facilitate our downstream analysis (Table 3). Additional literature supporting the use of compounds for each of the six classes described by Häuser et al, to treat FM patients is provided in Table 3 [76][77][78][79][80][81][82][83][84][85][86][87][88][89][90][91][92][93].…”

Section: Polypharmacy In Fmmentioning

confidence: 99%

“…Cording M et al, 2015 [76] Duloxetine (+)-(S)-N-Methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-amina Lunn MP et al, 2014 [77] Selective serotonin reuptake inhibitors [83] 2nd Generation…”

Section: Polypharmacy In Fmmentioning

confidence: 99%

“…Collatz A et al, 2016 [97] Proliferation inductor from B cells Although possibly not complete, Tables 3 and 4 include the most representative compounds to treat FM and ME/CFS according to the consulted authors [44,48,[76][77][78][79][80][81][82][83][84][85][86][87][88][89][90][91][92][93][99][100][101][102][103][104][105][106][107]. Unexpectedly, a single IUPAC overlap, corresponding to the Selective Serotonin Reuptake Inhibitor (SSRI) Fluoxetine, was found for drugs commonly prescribed for FM and ME/CFS (in bold in Tables 3 &4); indicating little prescription overlap at the IUPAC name level despite both groups of patients presenting common symptomatology.…”

Section: Othersmentioning

confidence: 99%

See 2 more Smart Citations

Impact of Polypharmacy on Candidate Biomarker miRNomes for the Diagnosis of Fibromyalgia and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Striking back on Treatments

Almenar-Pérez

Sánchez-Fito

Ovejero

et al. 2019

Preprint

View full text Add to dashboard Cite

Fibromyalgia (FM) and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) are diseases of unknown etiology presenting complex and often overlapping symptomatology. Despite promising advances on the study of miRNomes of these diseases, no validated molecular diagnostic biomarker yet exists. Since FM and ME/CFS patient treatments commonly include polypharmacy it is of concern that biomarker miRNAs are masked by drug interactions. Aiming at discriminating between drug-effects and true disease-associated differential miRNA expression, we evaluated the potential impact of commonly prescribed drugs on disease miRNomes, as reported by the literature. By using the web search tools SM2miR, Pharmaco-miR and repoDB, we found a list of commonly prescribed drugs that impact on FM and ME/CFS miRNomes and therefore could be interfering in the process of biomarker discovery. On another end, disease-associated miRNomes may incline patient´s response to treatment and toxicity. Here, we explored treatments for diseases in general that could be affected by FM and ME/CFS miRNomes finding a long list of them, including treatments for lymphoma, a type of cancer affecting ME/CFS patients at a higher rate than healthy population. We conclude that FM and ME/CFS miRNomes could help refine pharmacogenomic/pharmacoepigenomic analysis to elevate future personalized medicine and precision medicine programs in the clinic.

show abstract